American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Amazon Explores AI Content Marketplace With Media Publishers 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
WALTHAM, Mass., Feb. 20, 2018 -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Company Management will be presenting at two upcoming healthcare investor conferences.
- Canaccord Genuity 2018 Musculoskeletal Conference – New Orleans (March 6, 2018)
Adam Gridley, Histogenics’ CEO, will present a corporate overview on Tuesday, March 6, 2018 at 8:00 a.m. CT / 9:00 a.m. ET. The conference immediately precedes the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting and explores the current state of orthopedics, biologics, imaging, robotic surgery, tissue sculpting, and regenerative tissue companies.
- Cowen and Company 38th Annual Health Care Conference – Boston, MA (March 12-14, 2018)
Mr. Gridley will present a corporate overview on Wednesday, March 14, 2018 at 8:40 a.m. ET.
To access a live audio webcast of the presentations on the “Investor Relations” page of the Histogenics website, please click here. The webcasts will be available for approximately 45 days following the respective conferences.
About Histogenics Corporation
Histogenics (Nasdaq:HSGX) is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function. Histogenics’ lead investigational product, NeoCart®, is designed to rebuild a patient’s own knee cartilage to treat pain at the source and may prevent a patient’s progression to osteoarthritis. NeoCart is one of the most rigorously studied restorative cell therapies for orthopedic use. Histogenics recently completed enrollment of its NeoCart Phase 3 clinical trial and expects to report top-line, one-year superiority data in the third quarter of 2018. NeoCart is designed to perform like articular hyaline cartilage at the time of treatment, and as a result, may provide patients with more rapid pain relief and accelerated recovery as compared to the current standard of care. Histogenics’ technology platform has the potential to be used for a broad range of additional restorative cell therapy indications. For more information on Histogenics and NeoCart, please visit www.histogenics.com.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
